Hiru Corporation, and its primary subsidiary, Jiangxi Shuangshi Animal Health Products Co. (also known as Shuangshi AHP Co.) serve the Chinese agricultural market at home. HIRU focuses on developing, manufacturing and marketing a wide variety of veterinary products to the agricultural industry and has a solid reputation in the Chinese animal husbandry industry for offering quality products and solutions to farmers across the nation. Indeed, HIRU was awarded the prestigious Good Manufacturing Practice Certificate in 2005 and continues to expand its development and research to offer more and improved product lines for the Chinese agricultural industry.
Shuangshi AHP is not only part of Hiru Corp., it is also part of an industrial conglomerate known as Jiangxi Animal Health Products Co. Group. The Group anticipates realizing $227 million RMB (approximately $33 million USD) in annual sales, with average annual profits breaking approximately $66.5 million RMB (or $9.5 million USD), 30% of which is due to the efforts of Shuangshi AHP.
The Group chose Shuangshi AHP to join HIRU to enter the US markets with the belief that if the US market responds favorably to the company, and its business model and marketing strategy, the rest of the conglomerate will follow suit. Shuangshi AHP is using its presence on the US market to expand its Research and Development division so that it can introduce new veterinary medications to the Chinese industry in the coming years.
Hiru Corporation operates through its subsidiary, Jiangxi RongYu Pharmaceutical Group Inc., is a producer of Chinese herbs for the naturopathic industry in China. Jiangxi RongYu Pharmaceutical Group Co., Ltd. focuses on producing and manufacturing of herbs, herbal extracts and herbal preparations. HIRU’s products are based on the traditional Chinese systems. HIRU researches and develops dosage approaches and health applications of these traditional recipes. On December 3, 2009, HIRU completed the merger with the China-based company Jiangxi RongYu Pharmaceutical Group Inc.
To learn more about HIRU visit: http://www.hirucorporation.com
Power3 Medical Products Inc (OTC.BB:PWRM) has delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM’s diagnostic test, and focused on PWRM’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
Dr. Ira L. Goldknopf, PWRM’s President and Chief Scientific Officer, has stated: “In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease. It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which PWRM’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
PWRM filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.
Power3 Medical Products, Inc., a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States.
To learn more about PWRM visit: http://www.Power3Medical.com
SCOLR Pharma, Inc. (NYSE AMEX:DDD) reported financial results for the three and nine months ended September 30, 2010. Total revenues for the quarter ended September 30, 2010 were $124,000, a decrease of 53% compared to $262,000 for the same period in 2009. For the quarter ended September 30, 2010, the Company's marketing and selling expenses increased 56%, or $31,000, to $86,000 compared to $55,000 for the same period in 2009.
SCOLR Pharma, Inc., a pharmaceutical company, develops and commercializes prescription, over-the-counter, and nutritional products.
Dover Downs Gaming & Entertainment, Inc. (NYSE:DDE) released results for the three months ended September 30, 2010. Gaming revenues were up 8.6% compared to the third quarter of 2009. Slightly lower slot win was offset by table game revenue for the quarter, and to a lesser extent, slightly higher harness racing and sports wagering commissions. This was the first full quarter with live table games at the facility. The Company commenced table game operations on June 25, 2010.
Dover Downs Gaming & Entertainment, Inc., through its subsidiaries, operates as a gaming and entertainment company in the United States. The company?s operations consist of Dover Downs Casino.
ATMI, Inc. (Nasdaq:ATMI), announced recently it has acquired the Belgian biotechnology firm Artelis S.A., an innovator in the area of highly-efficient bioprocesses and technologies for cell culture research and manufacturing scale-up. The acquisition complements ATMI's leadership in ultra-pure single-use films, bioreactors, and mixing systems for characterizing, developing, and manufacturing biopharmaceuticals and extends its global capabilities to a broad range of biopharmaceutical process expertise.
ATMI, Inc. supplies various high-performance materials, materials packaging, and materials delivery systems with applications in the semiconductor, flat-panel display, and in the life sciences industries worldwide.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Hiru Corporation (OTCPK:HIRU)